Full field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 ePoster … testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 AAO 2020 poster by Allen Ho et al. … November 13, 2020
ARVO (2021) Russell SR et al., Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) Presentation … in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) ARVO 2021 presentation by Stephen … May 06, 2021
Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene ePoster … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … November 13, 2020
Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene Presentation … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … June 17, 2020
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 Press release … Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, Netherlands & CAMBRIDGE, Mass., April … April 13, 2021
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release … 2/3 Illuminate trial of sepofarsen for CEP290 -mediated Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation, also … January 04, 2022
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO) Press release … trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, … November 02, 2020
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Press release … call on July 20, 2020 at 5:00 pm EDT, which will focus on Leber congenital amaurosis 10 (LCA10) and the investigational RNA therapy for … July 13, 2020
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Press release … trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … October 10, 2019
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Press release … analysis of its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … September 05, 2018